TY - JOUR
T1 - NADPH-dependent oxidation of benzidine by rat liver
AU - Lakshmi, Vijaya M.
AU - Zenser, Nathan T.
AU - Hsu, F. F.
AU - Mattammal, Michael B.
AU - Zenser, Terry V.
AU - Davis, Bernard B.
N1 - Funding Information:
This work was supported by the Department of Veterans Affairs (TVZ and BBD). Mass spectrometry was performed at the Center of Mass Spectrometry Resource at Washington University School of Medicine (St Louis, MO) through NIH grants RR-00954 and AM-20579. The authors wish to thank Dr Jeff Kuo of the NMR facility at Washington University for NMR spectroscopy and Cindee Rettke and Priscilla DeHaven for excellent technical assistance.
PY - 1996/9
Y1 - 1996/9
N2 - This study used liver microsomes from control and β-naphthoflavone-treated rats to evaluate NADPH-dependent oxidation of benzidine. With microsomes from β-naphthoflavone-treated rats, the rates of formation of aqueous soluble metabolite (HPLC analysis) and protein and DNA binding were 835 ± 81, 14.5 ± 1.8 and 0.71 ± 0.14 pmol/ mg/min respectively. β-Naphthoflavone treatment elicited 12.3-, 1.8- and 14.2-fold increases in benzidine metabolism compared with controls as judged by HPLC and protein and DNA binding respectively. For microsomes from treated animals, K(m) and V(max) values were 47 ± 6 μM and 1.13 ± 0.14 nmol/mg protein/min respectively. All of the metabolic parameters were inhibited to varying degrees by glutathione (1 or 10 mM), N-acetylmethionine (10 mM) and ascorbic acid (10 mM). Following glutathione addition, at least two new metabolite peaks were observed, representing ~6% of the total radioactivity recovered by HPLC. Neither metabolite was 3-(glutathion-S-yl)benzidine. Cytochrome P450 inhibitors (10 μM) specific for different members of cytochrome gene families 1-3 indicated that benzidine was metabolized by cytochrome P450 1A1/1A2. Ellipticine and α-naphthoflavone, specific 1A1/1A2 inhibitors, elicited 50% inhibition at ~0.2 and 0.5 μM respectively. Electron impact and negative ion chemical ionization mass spectrometry identified the aqueous soluble metabolite as 3-hydroxybenzidine. The lability of 3-hydroxybenzidine observed at pH > 7.0 was prevented by ascorbic acid. Thus, cytochrome P450 1A1/1A2 NADPH-dependent metabolism of benzidine to 3-hydroxybenzidine was demonstrated.
AB - This study used liver microsomes from control and β-naphthoflavone-treated rats to evaluate NADPH-dependent oxidation of benzidine. With microsomes from β-naphthoflavone-treated rats, the rates of formation of aqueous soluble metabolite (HPLC analysis) and protein and DNA binding were 835 ± 81, 14.5 ± 1.8 and 0.71 ± 0.14 pmol/ mg/min respectively. β-Naphthoflavone treatment elicited 12.3-, 1.8- and 14.2-fold increases in benzidine metabolism compared with controls as judged by HPLC and protein and DNA binding respectively. For microsomes from treated animals, K(m) and V(max) values were 47 ± 6 μM and 1.13 ± 0.14 nmol/mg protein/min respectively. All of the metabolic parameters were inhibited to varying degrees by glutathione (1 or 10 mM), N-acetylmethionine (10 mM) and ascorbic acid (10 mM). Following glutathione addition, at least two new metabolite peaks were observed, representing ~6% of the total radioactivity recovered by HPLC. Neither metabolite was 3-(glutathion-S-yl)benzidine. Cytochrome P450 inhibitors (10 μM) specific for different members of cytochrome gene families 1-3 indicated that benzidine was metabolized by cytochrome P450 1A1/1A2. Ellipticine and α-naphthoflavone, specific 1A1/1A2 inhibitors, elicited 50% inhibition at ~0.2 and 0.5 μM respectively. Electron impact and negative ion chemical ionization mass spectrometry identified the aqueous soluble metabolite as 3-hydroxybenzidine. The lability of 3-hydroxybenzidine observed at pH > 7.0 was prevented by ascorbic acid. Thus, cytochrome P450 1A1/1A2 NADPH-dependent metabolism of benzidine to 3-hydroxybenzidine was demonstrated.
UR - http://www.scopus.com/inward/record.url?scp=0029789580&partnerID=8YFLogxK
U2 - 10.1093/carcin/17.9.1941
DO - 10.1093/carcin/17.9.1941
M3 - Article
C2 - 8824518
AN - SCOPUS:0029789580
SN - 0143-3334
VL - 17
SP - 1941
EP - 1947
JO - Carcinogenesis
JF - Carcinogenesis
IS - 9
ER -